These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 24642256)

  • 1. Inhibition of Mycobacterium tuberculosis topoisomerase I by m-AMSA, a eukaryotic type II topoisomerase poison.
    Godbole AA; Ahmed W; Bhat RS; Bradley EK; Ekins S; Nagaraja V
    Biochem Biophys Res Commun; 2014 Apr; 446(4):916-20. PubMed ID: 24642256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine learning and docking models for Mycobacterium tuberculosis topoisomerase I.
    Ekins S; Godbole AA; Kéri G; Orfi L; Pato J; Bhat RS; Verma R; Bradley EK; Nagaraja V
    Tuberculosis (Edinb); 2017 Mar; 103():52-60. PubMed ID: 28237034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Mycobacterium tuberculosis topoisomerase I by small-molecule inhibitors.
    Godbole AA; Ahmed W; Bhat RS; Bradley EK; Ekins S; Nagaraja V
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1549-57. PubMed ID: 25534741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of DNA topoisomerase I from Mycobacterium tuberculosis: DNA cleavage and religation properties and inhibition of its activity.
    Godbole AA; Leelaram MN; Bhat AG; Jain P; Nagaraja V
    Arch Biochem Biophys; 2012 Dec; 528(2):197-203. PubMed ID: 23085346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
    Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
    Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-Molecule Inhibitors Targeting Topoisomerase I as Novel Antituberculosis Agents.
    Sandhaus S; Annamalai T; Welmaker G; Houghten RA; Paz C; Garcia PK; Andres A; Narula G; Rodrigues Felix C; Geden S; Netherton M; Gupta R; Rohde KH; Giulianotti MA; Tse-Dinh YC
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4028-36. PubMed ID: 27114277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA topoisomerase I and DNA gyrase as targets for TB therapy.
    Nagaraja V; Godbole AA; Henderson SR; Maxwell A
    Drug Discov Today; 2017 Mar; 22(3):510-518. PubMed ID: 27856347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of potential Mycobacterium tuberculosis topoisomerase I inhibitors: a study against active, dormant and resistant tuberculosis.
    Sridevi JP; Suryadevara P; Janupally R; Sridhar J; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
    Eur J Pharm Sci; 2015 May; 72():81-92. PubMed ID: 25769524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel bacterial topoisomerase I inhibitors by use of in silico docking and in vitro assays.
    Sandhaus S; Chapagain PP; Tse-Dinh YC
    Sci Rep; 2018 Jan; 8(1):1437. PubMed ID: 29362471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
    Renuka J; Reddy KI; Srihari K; Jeankumar VU; Shravan M; Sridevi JP; Yogeeswari P; Babu KS; Sriram D
    Bioorg Med Chem; 2014 Sep; 22(17):4924-34. PubMed ID: 25129171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel gyrase B inhibitors as potential anti-TB drugs: homology modelling, hybrid virtual screening and molecular dynamics simulations.
    Maharaj Y; Soliman ME
    Chem Biol Drug Des; 2013 Aug; 82(2):205-15. PubMed ID: 23614896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target.
    Ravishankar S; Ambady A; Awasthy D; Mudugal NV; Menasinakai S; Jatheendranath S; Guptha S; Sharma S; Balakrishnan G; Nandishaiah R; Ramachandran V; Eyermann CJ; Reck F; Rudrapatna S; Sambandamurthy VK; Sharma UK
    Tuberculosis (Edinb); 2015 Sep; 95(5):589-98. PubMed ID: 26073894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions.
    Ketron AC; Denny WA; Graves DE; Osheroff N
    Biochemistry; 2012 Feb; 51(8):1730-9. PubMed ID: 22304499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shortening the treatment of tuberculosis.
    Mitchison DA
    Nat Biotechnol; 2005 Feb; 23(2):187-8. PubMed ID: 15696148
    [No Abstract]   [Full Text] [Related]  

  • 15. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH; Andersson BS; Nelson JA
    Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of novel ellipticines as potential anti-cancer agents.
    Deane FM; O'Sullivan EC; Maguire AR; Gilbert J; Sakoff JA; McCluskey A; McCarthy FO
    Org Biomol Chem; 2013 Feb; 11(8):1334-44. PubMed ID: 23314103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.
    Saxena S; Samala G; Renuka J; Sridevi JP; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2015 Apr; 23(7):1402-12. PubMed ID: 25766629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological activities of topopyrones.
    Zaleski PA; Maini R; Leiris SJ; Elban MA; Hecht SM
    J Nat Prod; 2012 Apr; 75(4):577-85. PubMed ID: 22462811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors.
    Chandran M; Renuka J; Sridevi JP; Pedgaonkar GS; Asmitha V; Yogeeswari P; Sriram D
    Int J Mycobacteriol; 2015 Jun; 4(2):104-15. PubMed ID: 26972878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
    BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.